Clinical Trials Logo

ALL, Childhood B-Cell clinical trials

View clinical trials related to ALL, Childhood B-Cell.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05366218 Recruiting - Clinical trials for Acute Lymphoid Leukemia Relapse

Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia

Anti-CD19-ALL
Start date: March 8, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of the trial is to evaluate the safety, clinical toxicity and in vivo immunological effects of MOR00208 in pediatric patients with acute lymphoblastic leukemia who showed newly emerging or persistent MRD after a first stem cell transplantation, received stem cell transplantation without having reached a sufficient molecular remission prior to transplant (defined as MRD ≥10E-4) irrespective of MRD after SCT or underwent a second or subsequent stem cell transplantation irrespective of MRD after SCT. Part I: to determine the recommended dose of MOR00208 in pediatric patients Part II: to evaluate the time until hematological relapse or increase of MRD